Revolutionizing pharmaceutical reporting with AI technology
A new collaboration will leverage generative artificial intelligence (AI) to transform the adverse event reporting process in the pharmaceutical industry. SK C&C has announced a partnership with Ilsung IS (formerly Ilsung Pharmaceuticals) to leverage the company's enterprise AI solution “Solur” to build an AI-based system for drug adverse event reporting.
Introducing efficiency and savings
Founded in 1954 as the first company to introduce antibiotics in Korea, Ilsung IS aims to increase efficiency and reduce costs across its operations by implementing hyper-automation through generative AI, cloud, and big data technologies.
Adapting to Regulatory Requirements with AI
Adverse event reports, essential for sharing any unwanted or unintended signs, symptoms, or diseases associated with drug use, are mandatory to be submitted by pharmaceutical companies. These reports range from a few to dozens every day. AI-enhanced “Solur” uses Korean Adverse Event Reporting System (KAERS) and Council of International Organizations of Medical Sciences (CIOMS) templates for international reporting to quickly organize and format these reports to meet regulatory requirements. The AI system is designed to facilitate reports from both medical professionals and patients, converting and organizing them into technical pharmaceutical terminology.
Plans for wider use of AI in pharmacovigilance
The two companies plan to develop a drug safety AI platform that is linked to a safety database (DB) in a cloud-native environment and expand the use of Solur to a variety of drug monitoring tasks.
Future global expansion and ongoing support
In addition, SK C&C is firm in its commitment to use “Solur” to leverage AI and data to support Ilsung IS's system-wide operations. The partnership signals an opportunity for expansion into the global pharmaceutical market, with ambitions for Japan.
Officials express their vision
Ilsung IS representatives were enthusiastic about how their adoption of Solur aligns with their ongoing efforts to introduce AI into new business areas in the pharmaceutical industry. Commenting on the potential of generative AI to minimize the risk of adverse events and create a safer drug use environment, SK C&C executives pledged to actively support Ilsung IS in realizing highly automated pharmaceutical operations while remaining flexible in a changing market.
Improving data accuracy and anonymity in safety reporting
Applying AI to drug safety reporting not only improves efficiency but also increases the accuracy and consistency of the data collected. AI systems can be trained to recognize and reduce human errors that can occur during manual data entry. Additionally, AI can assist in the anonymization process of reports to protect patient privacy, which is essential for complying with data protection regulations such as the General Data Protection Regulation (GDPR).
Gaining new insights from adverse event data
By applying advanced AI techniques to adverse event reporting, companies have the potential to uncover new insights into drug safety. AI algorithms can analyze large data sets and recognize patterns and correlations that are difficult for humans to detect, potentially improving our understanding of adverse events and contributing to drug development and safety.
Main challenges and controversies
– Data Privacy and Security: Integrating sensitive patient data with AI raises privacy and security concerns, and companies need to ensure that their AI systems comply with strict data protection regulations.
– Accuracy and reliability: The effectiveness of AI-generated reports depends on the quality of the data and algorithms used, and there are concerns that AI could propagate errors if not properly trained and monitored.
– Regulatory Approvals: Before AI-generated reports can be widely accepted, regulators need to be convinced of the reliability and validity of the AI process.
– Employment transition: Automating reporting could lead to job losses and create socio-economic challenges.
The Benefits of AI in Drug Safety Reporting
– Improved speed and efficiency of adverse event reporting.
– Consistency in reporting and reduced human error.
– Potential cost savings through automated processes.
– Ability to process and analyze large amounts of data to improve safety insights.
Shortcomings of AI in drug safety reporting
– The cost and complexity of initially setting up an AI system.
– Risk of job loss for professionals involved in pharmaceutical reporting activities.
– Uncertainty regarding the ongoing maintenance costs of AI systems.
Related Links:
For more information about drug safety and adverse event reporting, please visit:
– U.S. Food and Drug Administration (FDA)
– European Medicines Agency (EMA)
– World Health Organization (WHO)
While AI has the potential to enhance pharmacovigilance, it is important to note that the implementation of such technology must be done carefully to ensure compliance with all necessary standards and regulations. Additionally, the transition to AI-assisted systems will also require ongoing oversight to maintain the completeness and accuracy of safety reporting.
